

Specialty Pharmacy Program

Thalomid® (thalidomide)

DESCRIPTION

Thalomid is an immunomodulatory, anti-inflammatory, and anti-angiogenic agent. Thalomid is indicated for the treatment of multiple myeloma and erythema nodosum leprosum (ie, leprosy).

APPROVAL DURATION

Approval duration: 1 year

APPROVAL CRITERIA

FDA-Approved Indication(s)

1. Treatment of erythema nodosum leprosum.
2. Treatment of newly diagnosed multiple myeloma, in combination with dexamethasone.

Off-Label Indication(s)

Requests for off-label use of Thalomid will be reviewed and approved when sufficiently supported by evidence from major compendia, published peer-reviewed medical literature, nationally accepted practice guidelines, or expert consensus statements. The major compendia that are recognized include AHFS® Drug Information, Thomson Micromedex®, National Comprehensive Cancer Network Drugs and Biologics Compendium™, and Clinical Pharmacology.